Fig. 1
Prevalence of Abs against MAP epitopes in CD, UC and nIBD subjects. Distribution of Abs values based on the statistical analyses was performed separately for MAP3865c133–141 (a, b) and MAP3865c125–133 (c, d) with respect to disease. The dotted lines indicate the cut-off for positivity relative to each assay established through ROC analysis. The percentage of anti-MAP reactive subjects, statistically significant p values (CI 95%) and AUC are reported on top of each distribution. Horizontal bars specific for CD, UC and nIBD groups represent means